• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Evelo Biosciences Inc.

    7/21/23 3:46:59 PM ET
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVLO alert in real time by email
    SC 13G 1 hrzn20230721_sc13g.htm SCHEDULE 13G hrzn20230721_sc13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

     

     

    Evelo Biosciences, Inc.

    (Name of Issuer) 

     

     

    Common stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

    299734202

    (CUSIP Number)

     

     

    July 11, 2023

    (Date of Event Which Requires Filing of this Statement)

     


     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☒

    Rule 13d-l(b)

     

     

    ☐

    Rule 13d-l(c)

     

     

    ☐

    Rule 13d-l(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “file”" for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No.

    299734202

    1.

    Names of Reporting Persons:

     

    Horizon Technology Finance Corporation

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions):

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only:

     

     

    4.

    Citizenship or Place of Organization:

     

    State of Delaware

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With

    5.

    Sole Voting Power:

     

    2,164,502

    6.

    Shared Voting Power:

     

    0

    7.

    Sole Dispositive Power:

     

    2,164,502

    8.

    Shared Dispositive Power:

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person:  

     

    2,164,502

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):  

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9):

          

    11.5%

    12.

    Type of Reporting Person (See Instructions):

     

    IV  

     

     

     

     

    Item 1.

     

     

     

    (a)

    Name of Issuer:

     

    Evelo Biosciences, Inc.

     

     

    (b)

    Address of Issuer's Principal Executive Offices:

     

    620 Memorial Drive, 5th Floor

    Cambridge, MA 02139

     

    Item 2.

     

     

     

    (a)

    Name of Person Filing (the “Reporting Person”):

     

    Horizon Technology Finance Corporation

     

     

    (b)

    Address of Principal Business Office or, if none, Residence:

     

    312 Farmington Avenue

    Farmington, CT 06032

     

     

    (c)

    Citizenship:

     

    State of Delaware

     

     

    (d)

    Title of Class of Securities:

     

    Common stock, par value $0.001 per share

     

     

    (e)

    CUSIP Number:

     

    299734202

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

     

    (a)

    ☐

    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

           
     

    (b)

    ☐

    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

           
     

    (c)

    ☐

    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); 

           
     

    (d)

    ☒

    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

           
     

    (e)

    ☐

    An investment adviser in accordance with §240.13d-l(b)(l)(ii)(E);

           
     

    (f)

    ☐

    An employee benefit plan or endowment fund in accordance with §240.13d-l(b)(l)(ii)(F);

           
     

    (g)

    ☐

    A parent holding company or control person in accordance with § 240.13d-l(b)(l)(ii)(G);

           
     

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

           
     

    (i)

    ☐

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

           
     

    (j)

    ☐

    A non-U.S. institution in accordance with §240.13d-l(b)(l)(ii)(J);

           
     

    (k)

    ☐

    Group, in accordance with §240.13d-l(b)(l)(ii)(K).

     

     

     

     

    Item 4.

    Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

    (a)

    Amount beneficially owned:

     

    Aggregate beneficial ownership consists of 2,164,502 shares of comment stock.

     

    Horizon Technology Finance Corporation (the “Reporting Person”) owns directly 962,000 shares of common stock.

     

    Horizon Credit II LLC (“HCII”), a wholly owned direct subsidiary of the Reporting Person, owns directly 481,001 shares of common stock. The Reporting Person is the sole member and manager of HCII, with full voting and dispositive power. The Reporting Person may be deemed to have sole voting power and sole dispositive power in the shares of common stock held by HCII.

     

    Horizon Funding I, LLC (“HFI”), an indirect wholly owned subsidiary of the Reporting Person, owns directly 721,501 shares of common stock. The Reporting Person is the sole member and manager of Horizon Secured Loan Fund I LLC, which is the sole member and manager of HFI, and the Reporting Person has full voting and dispositive power. The Reporting Person may be deemed to have sole voting power and sole dispositive power in the shares of common stock held by HFI.

     

     

    (b)

    Percent of class:

     

    11.5%

     

     

    (c)

    Number of shares as to which the person has:

     

     

    (i)

    Sole power to vote or to direct the vote: 2,164,502

     

     

    (ii)

    Shared power to vote or to direct the vote: 0

     

     

    (iii)

    Sole power to dispose or to direct the disposition of: 2,164,502

     

     

    (iv)

    Shared power to dispose or to direct the disposition of: 0

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

     

     

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See item 4. above.

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.

    Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated: July 21, 2023

     

    HORIZON TECHNOLOGY FINANCE

    CORPORATION

     

     

    By:

     /s/ Robert D. Pomeroy, Jr.

       

    Robert D. Pomeroy, Jr.

       

    Chief Executive Officer

     

     

     
    Get the next $EVLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVLO

    DatePrice TargetRatingAnalyst
    11/2/2021$44.00 → $41.50Market Outperform
    JMP Securities
    11/1/2021$12.00Neutral → Buy
    Chardan Capital Markets
    6/23/2021$36.00 → $38.00Market Outperform
    JMP Securities
    6/23/2021$28.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities reiterated coverage on Evelo Biosciences with a new price target

      JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $41.50 from $44.00 previously

      11/2/21 7:54:09 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Evelo Biosciences from Neutral to Buy and set a new price target of $12.00

      11/1/21 8:36:16 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Evelo Biosciences with a new price target

      JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $38.00 from $36.00 previously

      6/23/21 1:58:41 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    SEC Filings

    See more
    • SEC Form EFFECT filed by Evelo Biosciences Inc.

      EFFECT - Evelo Biosciences, Inc. (0001694665) (Filer)

      3/11/24 12:15:15 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Evelo Biosciences Inc.

      15-12G - Evelo Biosciences, Inc. (0001694665) (Filer)

      1/26/24 5:30:25 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Evelo Biosciences Inc.

      S-8 POS - Evelo Biosciences, Inc. (0001694665) (Filer)

      1/26/24 5:29:48 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bodmer Mark converted options into 6,625 shares and sold $1,044 worth of shares (3,163 units at $0.33), increasing direct ownership by 16% to 25,732 units (SEC Form 4)

      4 - Evelo Biosciences, Inc. (0001694665) (Issuer)

      11/8/23 8:32:53 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mchale Duncan converted options into 6,500 shares and sold $1,024 worth of shares (3,103 units at $0.33), increasing direct ownership by 25% to 16,984 units (SEC Form 4)

      4 - Evelo Biosciences, Inc. (0001694665) (Issuer)

      11/8/23 8:32:28 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gill Simba sold $57 worth of shares (172 units at $0.33) and converted options into 1,172 shares, increasing direct ownership by 6% to 17,758 units (SEC Form 4)

      4 - Evelo Biosciences, Inc. (0001694665) (Issuer)

      11/8/23 8:31:56 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights

      – EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced its second quarter 2023 financial results and recent business highlights. Simba Gill, Ph.D., Evelo's Chief Executive Officer, said, "We are on track for a top line read

      8/14/23 7:30:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences Closes $25.5 Million Private Placement

      Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (the "Company" or "Evelo"), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share. The offering was led by Evelo's fo

      7/12/23 7:30:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Evelo Biosciences Inc. (Amendment)

      SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)

      12/11/23 9:09:54 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Evelo Biosciences Inc. (Amendment)

      SC 13G/A - Evelo Biosciences, Inc. (0001694665) (Subject)

      11/13/23 9:02:39 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Evelo Biosciences Inc.

      SC 13G - Evelo Biosciences, Inc. (0001694665) (Subject)

      8/10/23 8:19:47 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Financials

    Live finance-specific insights

    See more
    • Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

      CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 6076311. A live webcast of the event will also be available under "News and Events" in the Investors section of Eve

      3/17/22 7:00:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021

      CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 28, 2021, to report its third quarter 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 7574834. A live webcast of the event will also be available under "News and Events" in the Investors section of Evelo's website at h

      10/21/21 7:00:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

      CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 2021, to report its second quarter 2021 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 1658301. A live webcast of the event will also be available under "News and Events" in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be ava

      7/22/21 7:00:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evelo Biosciences Closes $25.5 Million Private Placement

      Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (the "Company" or "Evelo"), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share. The offering was led by Evelo's fo

      7/12/23 7:30:00 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellarity Appoints Dr. Gregory J. Moore to Board of Directors

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar

      6/6/23 8:00:00 AM ET
      $DNLI
      $DVA
      $EVLO
      $FHTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Misc Health and Biotechnology Services
      Biotechnology: Pharmaceutical Preparations